Edgewise Therapeutics (EWTX) Competitors $28.02 +0.02 (+0.07%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$28.49 +0.47 (+1.66%) As of 01/31/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EWTX vs. QGEN, ROIV, ASND, BPMC, BBIO, RVMD, LNTH, LEGN, ELAN, and CYTKShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Qiagen (QGEN), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Qiagen Roivant Sciences Ascendis Pharma A/S Blueprint Medicines BridgeBio Pharma Revolution Medicines Lantheus Legend Biotech Elanco Animal Health Cytokinetics Edgewise Therapeutics (NASDAQ:EWTX) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability. Do insiders & institutionals have more ownership in EWTX or QGEN? 70.0% of Qiagen shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor EWTX or QGEN? In the previous week, Qiagen had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 9 mentions for Qiagen and 6 mentions for Edgewise Therapeutics. Qiagen's average media sentiment score of 1.24 beat Edgewise Therapeutics' score of 0.24 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, EWTX or QGEN? Edgewise Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Which has stronger earnings and valuation, EWTX or QGEN? Qiagen has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$100.16M-$1.50-18.68Qiagen$1.97B5.04$341.30M$0.40111.32 Is EWTX or QGEN more profitable? Qiagen has a net margin of 4.73% compared to Edgewise Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.43% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -26.83% -25.67% Qiagen 4.73%13.43%8.10% Do analysts rate EWTX or QGEN? Edgewise Therapeutics presently has a consensus target price of $41.29, suggesting a potential upside of 47.34%. Qiagen has a consensus target price of $50.07, suggesting a potential upside of 12.13%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Edgewise Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Qiagen 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the MarketBeat Community believe in EWTX or QGEN? Qiagen received 215 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 72.34% of users gave Edgewise Therapeutics an outperform vote while only 60.73% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformEdgewise TherapeuticsOutperform Votes3472.34% Underperform Votes1327.66% QiagenOutperform Votes24960.73% Underperform Votes16139.27% SummaryQiagen beats Edgewise Therapeutics on 12 of the 17 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.69B$6.87B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-18.687.6680.0317.24Price / SalesN/A320.221,259.7283.26Price / CashN/A73.5045.9637.70Price / Book6.195.275.124.70Net Income-$100.16M$136.98M$111.40M$224.47M7 Day Performance-0.99%-0.84%2.30%-0.19%1 Month Performance4.94%-0.02%3.13%0.57%1 Year Performance46.09%7.51%24.60%20.35% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.1628 of 5 stars$28.02+0.1%$41.29+47.3%+57.2%$2.69BN/A-18.6860Insider TradeShort Interest ↑QGENQiagen4.0864 of 5 stars$45.49-0.3%$51.50+13.2%+5.2%$10.38B$1.97B116.635,967Upcoming EarningsStock SplitShort Interest ↓News CoveragePositive NewsROIVRoivant Sciences3.0968 of 5 stars$11.15-0.2%$17.93+60.9%+11.3%$8.11B$124.79M1.97860Analyst UpgradeASNDAscendis Pharma A/S3.4336 of 5 stars$126.05-1.7%$192.07+52.4%+0.6%$7.65B$288.08M-15.60640Upcoming EarningsAnalyst ForecastShort Interest ↓BPMCBlueprint Medicines0.9434 of 5 stars$113.88-0.9%$123.56+8.5%+41.5%$7.23B$249.38M-53.97640Short Interest ↑BBIOBridgeBio Pharma4.0242 of 5 stars$36.67-2.4%$48.08+31.1%-0.2%$6.93B$9.30M-15.22400Insider TradeShort Interest ↑News CoverageRVMDRevolution Medicines4.4555 of 5 stars$40.73-0.6%$66.25+62.7%+54.8%$6.85B$11.58M-11.35250LNTHLantheus4.5369 of 5 stars$98.31+0.8%$131.86+34.1%+78.1%$6.84B$1.30B16.36700Short Interest ↑News CoverageLEGNLegend Biotech3.2093 of 5 stars$36.64-0.7%$79.50+117.0%-30.8%$6.69B$285.14M-38.571,800Short Interest ↓ELANElanco Animal Health4.3179 of 5 stars$12.07-0.1%$16.43+36.1%-18.4%$5.97B$4.42B30.179,300Analyst ForecastNews CoverageCYTKCytokinetics3.9289 of 5 stars$49.94-1.6%$82.79+65.8%-36.7%$5.89B$7.53M-9.28250 Related Companies and Tools Related Companies Qiagen Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Revolution Medicines Competitors Lantheus Competitors Legend Biotech Competitors Elanco Animal Health Competitors Cytokinetics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EWTX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
